Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.8.0.1
Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Deficit [Member]
Non-Controlling Interest [Member]
Total
Balance at Dec. 31, 2017 $ 1 $ 40,895 $ 33,349,144 $ (26,082,960) $ 7,307,080
Balance, shares at Dec. 31, 2017 1,000 40,895,037        
Issuance of shares and warrants for cash $ 155 465,345 465,500
Issuance of shares and warrants for cash, shares 155,167        
Issuance of shares for services $ 210 1,207,090 1,207,500
Issuance of shares for services, shares 210,000        
Shares approved, not issued as of statement date $ 1,278 6,386,222 $ 6,387,500
Shares approved, not issued as of statement date, shares 1,277,500       1,277,500
Shares issued for purchase of patents $ 200 949,800 $ 950,000
Shares issued for purchase of patents, shares 200,000        
Purchase of Spirulinex, LLC joint venture interest (662,721) 662,721
Capital contributed by minority joint venturers 1,390 1,390
Net loss (8,508,190) (518) (8,508,190)
Balance at Mar. 31, 2018 $ 1 $ 42,738 $ 41,695,080 $ (34,591,150) $ 663,593 $ 7,810,262
Balance, shares at Mar. 31, 2018 1,000 42,737,704